Novo targets CagriSema FDA approval by year end and a US launch in early 2027

Novo Nordisk chief executive Mike Doustdar says the company hopes to win CagriSema FDA approval by the end of 2026 and to launch the weekly injection early in 2027. He gave the timeline in a Bloomberg interview on 4 November, the day Novo Nordisk third quarter results came out. CagriSema combines semaglutide with cagrilintide, an amylin analog, and has been under FDA review for weight management since December 2025. No decision has been announced, the price is undisclosed, and the drug stays at the filed stage on our board.

What Novo said about the CagriSema launch

Doustdar chose his words with care. "We are hopeful that we will be able to get the timely approval from the FDA at the end of this year and launch it at the beginning of next year," he told Bloomberg, according to a report by TheStreet. The written version is narrower. In its quarterly financial report, Novo said it is getting ready to bring CagriSema to the US market in early 2027, provided regulators approve it. That condition carries the whole plan. A launch date set by a company is a forecast, not a regulatory outcome, and the FDA has not published a decision date for the application. Novo filed for weight management in December 2025, citing the REDEFINE 1 and REDEFINE 2 trials, so the review has now run for close to a year.

Doustdar also described how Novo would bring the drug to patients if it is cleared. Bloomberg reported him saying the company is "already in production mode and training our team and staff to go not just through traditional channels, but through all channels." Telehealth platforms and Novo's own pharmacy service are expected to be central routes. Asked whether CagriSema would be offered direct to consumer from the first day, he answered "Yes, absolutely." He would not discuss cost. "We will not reveal our pricing strategy right now," he said, adding that the drug would be priced on the value it provides while taking patients into account. That leaves the most practical question for readers unanswered: what the medicine will cost and who will pay for it.

What the REDEFINE trials showed

The application rests on two Phase 3 trials in weight management. TheStreet put the average body weight reduction in REDEFINE 1 at 20.4% to 22.7% after 68 weeks, in adults with obesity or overweight who did not have type 2 diabetes. The same report gave a figure of roughly 13.7% for REDEFINE 2, which enrolled people who did have diabetes. The two studies drew on different populations, so the results should not be read side by side. Novo's third quarter update then added REDEFINE 9, in which the lower CagriSema dose produced 21% weight loss at week 68. The company's summary did not give a placebo figure or the trial size for that result, so its weight in the overall case is hard to judge from the outside.

TheStreet put the average body weight reduction in REDEFINE 1 at 20.4% to 22.7% after 68 weeks, in adults with obesity or overweight who did not have type 2 diabetes.

Across the programme, the most common side effects have involved the gut, including nausea, vomiting, diarrhoea and constipation. Novo has called that profile consistent with other incretin and amylin based therapies. Several details that shape CagriSema FDA approval are still not public, including whether the agency plans an advisory committee meeting and which doses Novo has asked it to approve. Readers should treat the timeline as the company's expectation. A review can run longer than a sponsor expects, and a launch also depends on supply. Doustdar's comment that Novo is already in production mode suggests it is building stock before a decision, but the company gave no volumes and no detail on which plants would make the drug.

REIMAGINE 5 and the tirzepatide question

The newest comparative data come from type 2 diabetes. In REIMAGINE 5, which Novo disclosed with its quarterly results, people on the lower CagriSema dose shed 12.4% of body weight, compared with 9.1% on low dose tirzepatide, Lilly's weekly GIP and GLP 1 injection, while the drop in HbA1c met the non inferiority bar at week 60. Novo describes the weight result as superior. It is the company's most direct head to head argument against tirzepatide, and our earlier look at REIMAGINE 5 covers it in more depth. The limit is dose. The trial paired lower doses of both drugs in people with diabetes, so it does not show how CagriSema compares with tirzepatide at full strength in people living with obesity.

An earlier diabetes trial adds context. In REIMAGINE 2, a 68 week Phase 3 study in 2,728 adults with type 2 diabetes, the higher CagriSema dose cut body weight by 14.2% against 10.2% for semaglutide alone, and lowered HbA1c by 1.91 percentage points against 1.76, as Novo reported in February 2026. Those figures assume that everyone stayed on treatment. The same release confirmed the December 2025 submission for weight management. A diabetes filing is a separate step, and Novo said it would discuss that pathway with regulators after the REIMAGINE 1 and REDEFINE 3 trials. The table below lists the public milestones that sit behind the current timeline.

Where the Wegovy pill leaves CagriSema

The launch plan sits inside a stronger quarter for Novo. Sales grew 4% at constant exchange rates on both an adjusted and a reported basis, while adjusted operating profit climbed 27% to DKK 31,720 million, flattered by DKK 9 billion of restructuring charges booked a year earlier. Novo raised its 2026 outlook and now expects adjusted sales and adjusted operating profit to land between minus 2% and plus 2% at constant exchange rates. The company said growth was led by obesity, and the Wegovy pill beat forecasts with DKK 5,394 million in quarterly sales after launches in the US, the UAE, the UK and Germany. Four more countries have followed since the quarter closed, so the tablet is now sold in eight.

Novo also said the Wegovy brand family accounts for over half of new US patients starting a branded obesity medicine, and that weekly new prescriptions for the Ozempic pill, launched in May, run at about twice the level Rybelsus saw before the switch. CagriSema would give Novo a third kind of obesity product next to the semaglutide pill and injection. Pipeline depth is part of the contest with Eli Lilly, and Novo started the AMAZE 9 Phase 3 trial of oral zenagamtide in September. Novo has said CagriSema could become the first combination treatment built on amylin, and the molecule would reach market ahead of several rivals on our amylin class tracker if CagriSema FDA approval comes on schedule.

Conclusion

CagriSema FDA approval is the next checkpoint, and for now it is Novo's hope rather than a fact. The application has been with the FDA since December 2025, the company is preparing a US launch for early 2027 if the drug is cleared, and its chief executive has promised direct sales without naming a price. REIMAGINE 5 gives Novo a comparative talking point, but only at low doses. Until the agency acts, CagriSema stays at the filed stage. This report is for research and news purposes and is not medical advice.